Bill Text: AZ HB2139 | 2015 | Fifty-second Legislature 1st Regular | Chaptered

Arizona House Bill 2139 (Prior Session Legislation)

Bill Title: Controlled substances; schedules

Spectrum: Partisan Bill (Republican 1-0)

Status: (Passed) 2015-03-17 - Chapter 27 [HB2139 Detail]

Download: Arizona-2015-HB2139-Chaptered.html

House Engrossed

State of Arizona

House of Representatives

Fifty-second Legislature

First Regular Session

2015

CHAPTER 27

HOUSE BILL 2139

AN ACT

Amending sections 36‑2512, 36‑2513, 36‑2514, 36‑2515 and 36‑2516, Arizona Revised Statutes; relating to the uniform controlled substances act.

(TEXT OF BILL BEGINS ON NEXT PAGE)

Be it enacted by the Legislature of the State of Arizona:

Section 1. Section 36-2512, Arizona Revised Statutes, is amended to read:

START_STATUTE36-2512. Substances in schedule I

A. The following controlled substances, unless specifically excepted, are included in schedule I:

1. Any of the following, including opiates and their isomers, esters, ethers, salts and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl‑alpha‑methylfentanyl.

(b) Acetylmethadol.

(b) (c) Allylprodine.

(d) Alphacetylmethadol, except levo‑alphacetylmethadol or LAAM.

(e) Alphameprodine.

(f) Alphamethadol.

(g) Alpha‑methylfentanyl.

(h) Alpha‑methylthiofentanyl.

(h) (i) Benzethidine.

(i) Benzylfentanyl and its optical isomers, salts and salts of isomers.

(j) Betacetylmethadol.

(j) (k) Beta‑hydroxyfentanyl.

(k) (l) Beta‑hydroxy‑3‑methylfentanyl.

(l) Betacetylmethadol.

(m) Betameprodine.

(n) Betamethadol.

(o) Betaprodine.

(p) Clonitazene.

(q) Dextromoramide.

(r) Diampromide.

(s) Diethylthiambutene.

(t) Difenoxin.

(u) Dimenoxadol.

(v) Dimepheptanol.

(w) Dimethylthiambutene.

(x) Dioxaphetyl butyrate.

(y) Dipipanone.

(z) Ethylmethylthiambutene.

(aa) Etonitazene.

(bb) Etoxeridine.

(cc) 4‑methylaminorex.

(dd) (cc) Furethidine.

(ee) (dd) Hydroxypethidine.

(ff) (ee) Ketobemidone.

(gg) (ff) Levomoramide.

(hh) (gg) Levophenacylmorphan.

(ii) MPPP (1‑methyl‑4‑phenyl‑4‑propionoxypiperidine).

(hh) 3‑methylfentanyl.

(ii) 3‑methylthiofentanyl.

(jj) Morpheridine.

(kk) MPPP(1‑methyl‑4‑phenyl‑4‑propionoxypiperidine).

(kk) (ll) Noracymethadol.

(ll) (mm) Norlevorphanol.

(mm) (nn) Normethadone.

(nn) (oo) Norpipanone.

(oo) (pp) Para‑fluorofentanyl.

(pp) (qq) Pepap PEPAP (1‑(2‑phenethyl)‑4‑phenyl‑4‑acetoxypiperidine).

(qq) (rr) Phenadoxone.

(rr) (ss) Phenampromide.

(ss) (tt) Phenomorphan.

(tt) (uu) Phenoperidine.

(uu) (vv) Piritramide.

(vv) (ww) Proheptazine.

(ww) (xx) Properidine.

(xx) (yy) Propiram.

(yy) (zz) Racemoramide.

(zz) Thenylfentanyl and its optical isomers, salts and salts of isomers.

(aaa) Thiofentanyl.

(bbb) 3‑methylfentanyl.

(ccc) 3‑methylthiofentanyl.

(ddd) (bbb) Tilidine.

(eee) (ccc) Trimeperidine.

2. Any of the following opium derivatives and their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Acetorphine.

(b) Acetyldihydrocodeine.

(d) Codeine methylbromide.

(e) Codeine‑n‑oxide.

(f) Cyprenorphine.

(g) Desomorphine.

(h) Dihydromorphine.

(i) Drotebanol.

(j) Etorphine, except hydrochloride salt.

(k) Heroin.

(l) Hydromorphinol.

(m) Methyldesorphine.

(n) Methyldihydromorphine.

(o) Morphine methylbromide.

(p) Morphine methylsulfonate.

(q) Morphine‑n‑oxide.

(r) Myrophine.

(s) Nicocodeine.

(t) Nicomorphine.

(u) Normorphine.

(v) Pholcodeine Pholcodine.

(w) Thebacon.

3. Any material, compound, mixture or preparation that contains any quantity of the following hallucinogenic substances and their salts, isomers and salts of isomers, unless specifically excepted or unless listed in another schedule, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation (for the purposes of this paragraph, "isomer" includes the optical, position and geometric isomers):

(a) Alpha‑ethyltryptamine (AET).

(a) (b) 4‑bromo‑2, 5‑dimethoxyamphetamine.

(b) (d) 2, 5‑dimethoxyamphetamine.

(e) 2,5-dimethoxy-4-ethylamphetamine (DOET).

(f) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7).

(d) (h) 5‑methoxy‑3, 4‑methylenedioxyamphetamine.

(e) (i) 4‑methyl‑2, 5‑dimethoxyamphetamine.

(j) 3,4-methylenedioxy amphetamine.

(f) (k) 3, 4‑methylenedioxymethamphetamine (MDMA).

(g) 3, 4‑methylenedioxy amphetamine.

(l) 3, 4‑methylenedioxy‑N‑ethylamphetamine (N-ethyl MDA, MDE, MDEA).

(m) N‑hydroxy‑3,4‑methylenedioxyamphetamine (N-hydroxy MDA).

(h) (n) 3, 4, 5‑trimethoxy amphetamine.

(i) Alpha‑ethyltryptamine.

(o) 5-methoxy-N,N,-dimethyltryptamine (5-MeO-DMT).

(p) Alpha-methyltryptamine (AMT).

(j) (q) Bufotenine.

(k) (r) Diethyltryptamine.

(l) (s) Dimethyltryptamine.

(t) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT).

(m) (u) Ibogaine.

(n) (v) Lysergic acid diethylamide.

(o) (w) Cannabis, except the synthetic isomer of delta‑9‑tetraydrocannabinol.

(p) (x) Mescaline.

(q) (y) Parahexyl.

(r) (z) Peyote.

(s) (aa) N‑ethyl‑3‑piperidyl benzilate.

(t) (bb) N‑methyl‑3‑piperidyl benzilate.

(u) N‑hydroxy‑3,4‑methylenedioxyamphetamine.

(v) N,N‑dimethylamphetamine.

(w) 3, 4‑methylenedioxy‑n‑ethylamphetamine.

(x) (cc) Psilocybin.

(y) (dd) Psilocyn.

(z) (ee) Ethylamine analog of phencyclidine.

(aa) (ff) Pyrrolidine analog of phencyclidine.

(bb) (gg) 1‑(1‑(2‑thienyl)cyclohexyl)pyrrolidine.

(cc) (hh) Thiophene analog of phencyclidine.

(dd) Aminorex.

(ee) 4‑bromo‑2,5‑dimethoxyphenethylamine.

(ff) 1-pentyl-3-(naphthoyl)indole (JWH-018 and isomers).

(gg) 1-butyl-3-(naphthoyl)indole (JWH-073 and isomers).

(hh) 1-hexyl-3-(naphthoyl)indole (JWH-019 and isomers).

(ii) 1-pentyl-3-(4-chloro naphthoyl)indole (JWH-398 and isomers).

(jj) 1-(2-(4-(morpholinyl)ethyl))-3-(naphthoyl)indole (JWH-200 and isomers).

(kk) 1-pentyl-3-(methoxyphenylacetyl)indole (JWH-250 and isomers).

(ll) (2-methyl-1-propyl-1h-indol-3-yl)-1-naphthalenyl-methanone (JWH‑015 and isomers).

(mm) (6ar,10ar)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol) (HU-210).

(nn) 5-(1,1-dimethylheptyl)-2-(3-hydroxycyclohexyl)-phenol (CP 47,497 and isomers).

(oo) 5-(1,1-dimethyloctyl)-2-(3-hydroxycyclohexyl)-phenol (cannabicyclohexanol, CP-47,497 C8 homologue and isomers).

(ii) 4-methylmethcathinone (Mephedrone).

(jj) 3,4-methylenedioxypyrovalerone (MDPV).

(kk) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E).

(ll) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D).

(mm) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).

(nn) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I).

(oo) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2).

(pp) 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4).

(qq) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H).

(rr) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N).

(ss) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P).

(tt) 3,4,-methylenedioxy-N-methylcathinone (Methylone).

(uu) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe, Cimbi-5).

(vv) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2- methoxybenzyl)ethanamine (25C-NBOMe, Cimbi-82).

(ww) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2- methoxybenzyl)ethanamine (25B-NBOMe, Cimbi-36).

(pp) 4. Any material, compound, mixture or preparation which contains any quantity of cannabimimetic substances and their salts, isomers, whether optical, positional or geometric, and salts of isomers, unless specifically excepted, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation.� For the purposes of this subdivision, "cannabimimetic substances" means any substances within the following structural classes:

(i) (a) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5‑position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent. Substances in the 2‑(3‑hydroxycyclohexyl)phenol generic definition include CP-47,497, CP‑47,497 C8‑Homolog, CP-55,940 and CP-56,667.

(ii) (b) 3-(naphthoyl)indole or 3-(naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.� Substances in the 3‑(naphthoyl)indole generic definition include AM-678, AM-2201, JWH-004, JWH‑007, JWH-009, JWH‑015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-046, JWH‑047, JWH-048, JWH‑049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH‑076, JWH-079, JWH‑080, JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH‑116, JWH-120, JWH‑122, JWH-148, JWH-149, JWH-175, JWH-180, JWH-181, JWH‑182, JWH-184, JWH‑185, JWH-189, JWH-192, JWH-193, JWH-194, JWH-195, JWH‑196, JWH-197, JWH‑199, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH‑234, JWH-235, JWH‑236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-262, JWH‑386, JWH-387, JWH‑394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH‑412, JWH-413, JWH‑414 and JWH-415.

(iii) (c) 3-(naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent. Substances in the 3-(naphthoyl)pyrrole generic definition include JWH-030, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH‑245, JWH‑246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-346, JWH-348, JWH‑363, JWH‑364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH‑373 and JWH-392.

(iv) (d) 1-(naphthylmethylene)indene by substitution of the 3‑position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent. Substances in the 1-(naphthylmethylene)indene generic definition include JWH‑176.

(v) (e) 3-(phenylacetyl)indole or 3-(benzoyl)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent. Substances in the 3-(phenylacetyl)indole generic definition include AM-694, AM‑2233, JWH-167, JWH-201, JWH-202, JWH-203, JWH‑204, JWH‑205, JWH‑206, JWH‑207, JWH-208, JWH-209, JWH-237, JWH-248, JWH‑250, JWH‑251, JWH‑253, JWH‑302, JWH-303, JWH-304, JWH-305, JWH-306, JWH‑311, JWH‑312, JWH‑313, JWH‑314, JWH-315, JWH-316, RCS-4, RCS-8, SR‑18 and SR‑19.

(vi) (f) 3-(cyclopropylmethanone) indole or 3-(cyclobutylmethanone) indole or 3‑(cyclopentylmethanone) indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl rings to any extent. Substances in the 3‑(cyclopropylmethanone) indole generic definition include UR‑144, Fluoro‑UR‑144 and XLR‑11.

(g) Other substances:

(i) (6ar,10ar)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol) (HU-210).

(ii) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48).

(iii) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22).

(iv) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22).

(v) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA).

(vi) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA).

4. 5. Any of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers, unless specifically excepted or listed in another schedule, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Mecloqualone.

(b) Methaqualone.

5. 6. Gamma‑hydroxybutyric acid, any salt, hydroxybutyric compound, derivative or preparation of gamma‑hydroxybutyric acid, including any isomers, esters and ethers and salts of isomers, esters and ethers of gamma‑hydroxybutyric acid, except gamma‑butyrolactone if the existence of the isomers, esters and salts is possible within the specific chemical designation.� Notwithstanding any other provision of the federal food, drug and cosmetic act, for purposes of security requirements imposed by law or regulation on registered distributors and registered manufacturers, this substance if manufactured, distributed or processed in accordance with an exemption approved under section 505 of the federal food, drug and cosmetic act is a controlled substance in schedule III pursuant to section 36‑2514.

6. 7. Any of the following stimulants including their salts, isomers and salts of isomers, unless specifically excepted or listed in another schedule, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Alpha-methylaminovalerophenone (Pentedrone).

(a) (b) Alpha-pyrrolidinobutiophenone (Alpha-PBP).

(b) (c) Alpha-pyrrolidinopropiophenone (Alpha-PPP).

(e) Aminorex.

(f) N-benzylpiperazine (BZP).

(d) (g) Beta-keto-n‑methylbenzodioxolylbutanamine (Butylone).

(e) (h) Beta-keto-n‑methylbenzodioxolylpentanamine (Pentylone).

(f) (i) Cathinomimetic substances which are any substances derived from cathinone, (2-amino-1-phenyl-1-propanone) by any substitution at the phenyl ring, any substitution at the 3 position, any substitution at the nitrogen atom or any combination of the above substitutions.

(g) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).

(h) (j) (+)cis‑4‑methylaminorex((+)cis‑4,5‑dihydro‑4‑methyl‑5‑phenyl-2-oxazolamine).

(i) (k) Dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI).

(j) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E).

(k) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D).

(l) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N).

(m) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P).

(n) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H).

(o) (l) Dimethylcathinone (Metamfepramone).

(p) (m) Ethcathinone.

(q) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2).

(r) (n) Fenethylline.

(s) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I).

(t) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4).

(o) 3-fluoro-N-methylcathinone (3-FMC).

(p) 4-fluoro-N-methylcathinone (4-FMC, Flephedrone).

(u) (q) Methcathinone.

(v) (r) Methoxy-alpha-pyrrolidinopropiophenone (MOPPP).

(w) (s) Methoxyphenethylamine mimetic substances which are any substances derived from 2, 5-dimethoxy-phenethylamine by any substitution at the phenyl ring, any substitution at the nitrogen atom or any combination of the above substitutions.

(x) (t) Methyl-a-pyrrolidinobutiophenone (MPBP).

(u) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP).

(v) 4-methyl-N-ethylcathinone (4-MEC).

(y) (w) Methylenedioxy-alphapyrrolidinopropiophenone (MDPPP).

(z) (x) Methylenedioxyethcathinone (Ethylone).

(aa) (y) N‑ethylamphetamine.

(z) Naphthypyrovalerone (Naphyrone).

(aa) N,N-dimethylamphetamine.

B. The board may except by rule any compound, mixture or preparation containing any substance listed in this section from the application of all or any part of this chapter if the compound, mixture or preparation contains one or more active medicinal ingredients and if the admixtures are included therein in combinations, quantity, proportion or concentration that vitiates the potential for abuse. END_STATUTE

Sec. 2. Section 36-2513, Arizona Revised Statutes, is amended to read:

START_STATUTE36-2513. Substances in schedule II

A. The following controlled substances are, unless specifically excepted, are included in schedule II:

1. Any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by combination of extraction and chemical synthesis:

(a) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone and their respective salts, but including the following:

(i) Raw opium.

(ii) Opium extracts.

(iii) Opium fluid extracts.

(iv) Powdered opium.

(v) Granulated opium.

(vi) Tincture of opium.

(vii) Codeine.

(viii) Dihydroetorphine.

(viii) (ix) Ethylmorphine.

(ix) (x) Etorphine hydrochloride.

(x) (xi) Hydrocodone.

(xi) (xii) Hydromorphone.

(xii) (xiii) Metopon.

(xiii) (xiv) Morphine.

(xv) Oripavine.

(xiv) (xvi) Oxycodone.

(xv) (xvii) Oxymorphone.

(xvi) (xviii) Thebaine.

(xvii) Levo‑alphacetylmethadol.

(b) Any salt, compound, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in subdivision (a) of this paragraph, except that these substances shall not include the isoquinoline alkaloids of opium.

(d) Coca leaves and any salt, compound, derivative or preparation of coca leaves, including cocaine and its optical isomers ecgonine and their salts, isomers, derivatives and salts of isomers and derivatives, and any salt, compound, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.

(e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrine phenanthrene alkaloids of the opium poppy).

2. Any of the following, including opiates, and including isomers, esters, ethers, salts and salts of isomers, of the following esters and ethers, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted:

(a) Alfentanil.

(b) Alphaprodine.

(d) Bezitramide.

(e) Bulk dextropropoxyphene (nondosage forms).

(e) (f) Carfentanil.

(f) (g) Dihydrocodeine.

(g) (h) Diphenoxylate.

(h) (i) Fentanyl.

(j) Fentanyl immediate precursor, 4-anilino-N-phenethyl-4-piperidine (ANPP).

(i) (k) Isomethadone.

(l) Levo-alphacetylmethadol (LAAM).

(j) (m) Levomethorphan.

(k) (n) Levorphanol.

(l) (o) Metazocine.

(m) (p) Methadone.

(n) (q) Methadone-‑intermediate, 4‑cyano‑2‑dimethylamino‑4,

4‑diphenylbutane.

(o) (r) Moramide‑‑intermediate, 2‑methyl‑3‑morpholino‑1,

1‑diphenylpropane‑carboxylic acid.

(p) Nabilone.

(q) (s) Pethidine (meperidine).

(r) (t) Pethidine‑‑intermediate‑‑A, 4-cyano-1-methyl-

4-phenylpiperidine.

(s) (u) Pethidine‑‑intermediate‑‑B, ethyl-4-phenylpiperidine-

4-carboxylate.

(t) (v) Pethidine‑‑intermediate‑‑C, 1-methyl-4-phenylpiperidine-

4‑carboxylic acid.

(u) (w) Phenazocine.

(v) Phenylacetone.

(w) 1‑(2‑phenylethyl)‑4‑phenyl‑4‑acetyloxpiperidine (pepap),

including its optical isomers, salts and salts of isomers.

(x) Piminodine.

(y) Racemethorphan.

(z) Racemorphan.

(aa) Remifentanil.

(aa) (bb) Sufentanil.

(bb) Remifentanil.

(cc) Tapentadol.

3. Any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:

(a) Amphetamine and its salts, optical isomers and salts of its optical isomers.

(b) Methamphetamine, including its salts, isomers and salts of isomers.

(d) Methylphenidate.

(e) Phenylacetone (immediate precursor to amphetamine and methamphetamine).

(f) Lisdexamfetamine, and its salts, isomers and salts of isomers.

4. Any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Amobarbital.

(b) Glutethimide.

(d) Phencyclidine.

(e) Phencyclidine immediate precursors:

(i) 1‑phenylcyclohexylamine.

(ii) 1‑piperidinocyclohexanecarbonitrile (PCC).

(f) Secobarbital.

5. Nabilone (hallucinogenic substance).

Sec. 3. Section 36-2514, Arizona Revised Statutes, is amended to read:

START_STATUTE36-2514. Substances in schedule III; definition

A. The following controlled substances are, unless specifically excepted, are included in schedule III:

1. Any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system, including its salts, isomers, whether optical, position or geometric, and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Benzphetamine.

(b) Chlorphentermine.

(d) Delta‑9‑tetrahydrocannabinol (synthetic).

(e) Gamma-hydroxybutyric acid, any salt, hydroxybutyric compound, derivative or preparation of gamma‑hydroxybutyric acid, including isomers, esters and ethers and salts of isomers, esters and ethers of gamma‑hydroxybutyric acid, except gamma‑butyrolactone, contained in a drug product for which an application has been approved under section 505 of the federal food, drug and cosmetic act.

(f) Ketamine.

(g) (d) Phendimetrazine.

2. Any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

(a) Any compound, mixture or preparation containing amobarbital, secobarbital, pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.

(b) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital or any salt of any of these drugs and approved by the federal act for marketing only as a suppository.

(d) Chlorhexadol.

(e) Embutramide.

(f) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers and salts of isomers, for which an application is approved under section 505 of the federal food, drug, and cosmetic act.

(g) Ketamine, and its salts, isomers and salts of isomers.

(e) (h) Lysergic acid.

(f) (i) Lysergic acid amide.

(g) (j) Methyprylon.

(k) Perampanel, and its salts, isomers and salts of isomers.

(h) (l) Sulfondiethylmethane.

(i) (m) Sulfonethylmethane.

(j) (n) Sulfonmethane.

(k) (o) Tiletamine/zolazepam (telazol) or any salt thereof.

3. Any material, compound, mixture or preparation containing the narcotic drug nalorphine� or any of its salts.

4. Any material, compound, mixture or preparation containing the narcotic drug buprenorphine or any of its salts.

5. Any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof, calculated as the free anhydrous base or alkaloid:

(a) Not more than one point eight grams of codeine, or any of its salts, per one hundred milliliters or not more than ninety milligrams per dosage unit with an equal or greater quantity of an isoquinoline alkaloid of opium.

(b) Not more than one point eight grams of codeine, or any of its salts, per one hundred milliliters or not more than ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(c) Not more than three hundred milligrams of dihydrocodeinone, or any of its salts, per one hundred milliliters or not more than fifteen milligrams per dosage unit with a fourfold or greater quantity of an isoquinoline alkaloid of opium.

(d) Not more than three hundred milligrams of dihydrocodeinone, or any of its salts, per one hundred milliliters or not more than fifteen milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(e) (c) Not more than one point eight grams of dihydrocodeine, or any of its salts, per one hundred milliliters or not more than ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(f) (d) Not more than three hundred milligrams of ethylmorphine, or any of its salts, per one hundred milliliters or not more than fifteen milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(g) (e) Not more than five hundred milligrams of opium per one hundred milliliters or per one hundred grams or not more than twenty‑five milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(h) (f) Not more than fifty milligrams of morphine, or any of its salts, per one hundred milliliters or per one hundred grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

6. Any material, compound, mixture or preparation containing any of the following anabolic steroids but not including United States food and drug administration approved over‑the‑counter preparations, labeled for animal use or those prescription‑only anabolic steroid preparations in combination with a therapeutic amount of a nonanabolic steroid and intended for human use an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the United States food and drug administration for such administration:

(a) 3beta, 17-dihydroxy-5a-androstane.

(b) 3alpha, 17beta-dihydroxy-5a-androstane.

(d) 3beta, 17beta-dihydroxy-5alpha-androst-1-ene.

(e) 3alpha, 17beta-dihydroxy-5alpha-androst-1-ene.

(f) 4-androstenediol.

(g) 5-androstenediol.

(h) 1-androstenedione.

(i) 4-androstenedione.

(j) 5-androstenedione.

(k) Bolasterone.

(a) (l) Boldenone.

(b) Chlorotestosterone.

(m) Boldione.

(n) Calusterone.

(d) (p) Dehydrochlormethyltestosterone.

(e) Dihydrotestosterone.

(q) Desoxymethyltestosterone.

(r) Delta1-dihydrotestosterone.

(s) 4-dihydrotestosterone.

(f) (t) Drostanolone.

(g) (u) Ethylestrenol.

(h) (v) Fluoxymesterone.

(i) Formebulone.

(w) Formebolone.

(x) Furazabol.

(y) 13beta-ethyl-17beta-hydroxygon-4-en-3-one.

(z) 4-hydroxytestosterone.

(aa) 4-hydroxy-19-nortestosterone.

(bb) Mestanolone.

(j) (cc) Mesterolone.

(k) (dd) Methandienone.

(l) Methandranone.

(m) (ee) Methandriol.

(n) Methandrostenolone.

(ff) Methasterone.

(o) (gg) Methenolone.

(hh) 17alpha-methyl-3beta, 17beta-dihydroxy-5a-androstane.

(ii) 17alpha-methyl-3alpha, 17beta-dihydroxy-5a-androstane.

(jj) 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-ene.

(kk) 17alpha-methyl-4-hydroxynandrolone.

(ll) Methyldienolone.

(mm) Methyltrienolone.

(p) (nn) Methyltestosterone.

(q) (oo) Mibolerone.

(pp) 17alpha-methyl-delta1-dihydrotestosterone.

(r) (qq) Nandrolone.

(rr) 3beta, 17beta-dihydroxyestr-4-ene.

(ss) 3alpha, 17beta-dihydroxyestr-4-ene.

(tt) 3beta, 17beta-dihydroxyestr-5-ene.

(uu) 3alpha, 17beta-dihydroxyestr-5-ene.

(vv) 19-nor-4,9(10)-androstadienedione.

(ww) 19-nor-4-androstenedione.

(xx) 19-nor-5-androstenedione.

(yy) Norbolethone.

(zz) Norclostebol.

(s) (aaa) Norethandrolone.

(bbb) Normethandrolone.

(t) (ccc) Oxandrolone.

(u) (ddd) Oxymesterone.

(v) (eee) Oxymetholone.

(fff) Prostanozol.

(w) Stanolone.

(x) (ggg) Stanozolol.

(hhh) Stenbolone.

(y) (iii) Testolactone.

(z) (jjj) Testosterone.

(kkk) Tetrahydrogestrinone.

(aa) (lll) Trenbolone.

(bb) (mmm) Any salt, ester or isomer of a drug or substance described or listed in this paragraph, if that salt, ester or isomer promotes muscle growth.

7. Dronabinol, (synthetic delta-9-tetrahyrocannabinol) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product (hallucinogenic substance).

B. If any person prescribes, dispenses or distributes an anabolic steroid for human use that has been approved by the United States food and drug administration for the express intent of administration through implants to cattle or other nonhuman species, the person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this section.

B. C. The board may except by rule any compound, mixture or preparation containing any substance listed in this section from the application of all or any part of this chapter if the compound, mixture or preparation contains one or more active medicinal ingredients and if the admixtures are included therein in combinations, quantity, proportion or concentration that vitiates the potential for abuse.

C. D. For the purposes of this section, "anabolic steroid" means a growth promoting drug or hormonal substance that is chemically or pharmacologically related to testosterone, other than estrogens, progestins, and corticosteroids and dehydroepiandrosterone. END_STATUTE

Sec. 4. Section 36-2515, Arizona Revised Statutes, is amended to read:

START_STATUTE36-2515. Substances in schedule IV

A. The following controlled substances are, unless specifically excepted, are included in schedule IV:

1. Any material, compound, mixture or preparation that contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system, including its salts, isomers, whether optical, position or geometric, and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Cathine (+(4)‑norpseudoephedrine).

(b) Diethylpropion.

(d) Fenproporex.

(e) Mazindol.

(f) Mefenorex.

(g) Modafinil.

(g) (h) Pemoline (including organometallic complexes and chelates thereof).

(h) (i) Phentermine.

(i) (j) Pipradrol.

(k) Sibutramine.

(j) (l) SPA((‑)‑1‑dimethylamino‑1, 2‑diphenylethane).

(k) Butorphanol.

(l) Modafinil.

(m) Sibutramine.

(n) Butylone.

(o) Fluoromethcathinone.

(p) Methoxymethcathinone.

(q) Methylenedioxymethcathinone.

(r) Methylenedioxypyrovalerone.

(s) Methylmethcathinone.

(t) Naphthylpyrovalerone.

2. Any material, compound, mixture or preparation that contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Alfaxalone.

(a) (b) Alprazolam.

(b) (c) Barbital.

(d) (e) Camazepam.

(f) Carisoprodol.

(e) (g) Chloral betaine.

(f) (h) Chloral hydrate.

(g) (i) Chlordiazepoxide.

(h) (j) Clobazam.

(i) (k) Clonazepam.

(j) Chlorazepate.

(l) Clorazepate.

(k) (m) Clotiazepam.

(l) (n) Cloxazolam.

(m) (o) Delorazepam.

(n) (p) Diazepam.

(o) (q) Dichloralphenazone.

(p) (r) Estazolam.

(q) (s) Ethchlorvynol.

(r) (t) Ethinamate.

(s) (u) Ethyl loflazepate.

(t) (v) Fludiazepam.

(u) (w) Flunitrazepam.

(v) (x) Flurazepam.

(y) Fospropofol.

(w) (z) Halazepam.

(x) (aa) Haloxazolam.

(y) (bb) Ketazolam.

(z) (cc) Loprazolam.

(aa) (dd) Lorazepam.

(bb) (ee) Lormetazepam.

(cc) (ff) Mebutamate.

(dd) (gg) Medazepam.

(ee) (hh) Meprobamate.

(ff) (ii) Methohexital.

(gg) (jj) Methylphenobarbital (methobarbital).

(hh) (kk) Midazolam.

(ii) (ll) Nimetazepam.

(jj) (mm) Nitrazepam.

(kk) (nn) Nordiazepam.

(ll) (oo) Oxazepam.

(mm) (pp) Oxazolam.

(nn) (qq) Paraldehyde.

(oo) (rr) Petrichloral.

(pp) (ss) Phenobarbital.

(qq) (tt) Pinazepam.

(rr) (uu) Prazepam.

(ss) (vv) Quazepam.

(ww) Suvorexant.

(tt) (xx) Temazepam.

(uu) (yy) Tetrazepam.

(vv) (zz) Triazolam.

(ww) (aaa) Zaleplon.

(xx) (bbb) Zolpidem.

(ccc) Zopiclone.

3. Fenfluramine, and its salts, isomers, whether optical, position or geometric, and its salts of isomers, whenever the existence of such salts, isomers and salts of isomers is possible.

4. Any material, compound, mixture or preparation containing any of the following narcotic drugs, or their salts, calculated as the free anhydrous base or alkaloid, in limited quantities of not more than one milligram of difenoxin and not less than twenty‑five micrograms of atropine sulfate per dosage unit. as set forth below:

(a) Not more than one milligram of difenoxin and not less than twenty‑five micrograms of atropine sulfate per dosage unit.

(b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane.

(c) Tramadol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol, and its salts, optical and geometric isomers, and its salts of isomers.

5. Any material, compound, mixture or preparation that contains any quantity of the following substances, including its salts:

(a) Carisoprodol.

(b) Dextropropoxyphene (alpha‑(+)‑4‑dimethylamino‑1, 2‑diphenyl‑ 3‑methyl‑2‑propionoxybutane).

(b) Butorphanol, including its optical isomers.

6. Lorcaserin, and its salts, isomers and salts of isomers, whenever the existence of such salts, isomers and salts of isomers is possible.

Sec. 5. Section 36-2516, Arizona Revised Statutes, is amended to read:

START_STATUTE36-2516. Substances in schedule V

The following controlled substances or controlled substance precursors are included in schedule V:

1. Any compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or their salts, calculated as the free anhydrous base or alkaloid, which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

(a) Not more than two hundred milligrams of codeine, or any of its salts, per one hundred milliliters or per one hundred grams.

(b) Not more than one hundred milligrams of dihydrocodeine, or any of its salts, per one hundred milliliters or per one hundred grams.

(c) Not more than one hundred milligrams of ethylmorphine, or any of its salts, per one hundred milliliters or per one hundred grams.

(d) Not more than 2.5 milligrams of diphenoxylate and not less than twenty‑five micrograms of atropine sulfate per dosage unit.

(e) Not more than one hundred milligrams of opium per one hundred milliliters or per one hundred grams.

(f) Not more than 0.5 milligram of difenoxin and not less than twenty‑five micrograms of atropine sulfate per dosage unit.

2. Unless specifically excepted or listed in another schedule, any material, compound, mixture or preparation containing pyrovalerone.

3. Any compound or preparation containing the single active ingredient ephedrine or any of its salts.

4. Unless specifically excepted or listed in another schedule in this article, any material, compound, mixture or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:

(a) Ezogabine.

(b) Lacosamide.